Pragmatic Comparative Clinical Trial to Determine Optimal Initial Therapy for Multiple Myeloma

Overview

About this study

The purpose of this study is to compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed Multiple Myeloma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Previously untreated active multiple myeloma starting a new treatment for their disease with one of the three established treatment regimens: VRd, DRd, or DVRd.
No prior treatment for myeloma.
Not receiving concurrent treatment for another active malignancy.
No more than 3 months from start of treatment.

Exclusion Criteria:

< 18 years of age.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/21/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Shaji Kumar, M.D.	Open for enrollment	Contact information: Shaji Kumar M.D. (507) 284-5096 Kumar.Shaji@mayo.edu
La Crosse, Wis. Mayo Clinic principal investigator Anna Jones, M.D.	Contact us for the latest status	Contact information: Sarah Aug (507) 284-0284 pragmmatic@mayo.edu
Jacksonville, Fla. Mayo Clinic principal investigator Sikander Ailawadhi, M.D.	Open for enrollment	Contact information: Sikander Ailawadhi M.D. Ailawadhi.Sikander@mayo.edu
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Saurabh Chhabra, M.B.B.S., M.D.	Open for enrollment	Contact information: Saurabh Chhabra M.B.B.S., M.D. (480) 342-5852 Chhabra.Saurabh@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Open for enrollment

Contact information:

Shaji Kumar M.D.

(507) 284-5096

Kumar.Shaji@mayo.edu

La Crosse, Wis.

Mayo Clinic principal investigator

Anna Jones, M.D.

Contact us for the latest status

Contact information:

Sarah Aug

(507) 284-0284

pragmmatic@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Sikander Ailawadhi, M.D.

Open for enrollment

Contact information:

Sikander Ailawadhi M.D.

Ailawadhi.Sikander@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Saurabh Chhabra, M.B.B.S., M.D.

Open for enrollment

Contact information:

Saurabh Chhabra M.B.B.S., M.D.

(480) 342-5852

Chhabra.Saurabh@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials